Corebridge Financial Inc. Has $9.68 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Corebridge Financial Inc. trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,131 shares of the company's stock after selling 1,230 shares during the period. Corebridge Financial Inc. owned about 0.09% of Medpace worth $9,678,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Centaurus Financial Inc. increased its stake in shares of Medpace by 2.0% during the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company's stock worth $505,000 after purchasing an additional 29 shares during the last quarter. Lindbrook Capital LLC boosted its holdings in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after purchasing an additional 29 shares in the last quarter. HBK Sorce Advisory LLC increased its position in Medpace by 0.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock worth $1,789,000 after buying an additional 29 shares during the last quarter. Assetmark Inc. raised its holdings in Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after buying an additional 29 shares in the last quarter. Finally, Proficio Capital Partners LLC lifted its position in shares of Medpace by 4.1% in the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after buying an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Leerink Partners initiated coverage on Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective on the stock. Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Finally, Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $376.30.

Medpace Stock Performance

MEDP traded down $7.67 during midday trading on Monday, hitting $304.69. The company had a trading volume of 602,622 shares, compared to its average volume of 299,947. Medpace Holdings, Inc. has a twelve month low of $289.01 and a twelve month high of $459.77. The firm's 50-day simple moving average is $335.25 and its 200-day simple moving average is $338.90. The company has a market capitalization of $9.28 billion, a PE ratio of 24.12, a P/E/G ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.